Resona Asset Management Co. Ltd. Sells 3,352 Shares of IQVIA Holdings Inc. $IQV

Resona Asset Management Co. Ltd. reduced its stake in IQVIA Holdings Inc. (NYSE:IQV) by 6.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 52,882 shares of the medical research company’s stock after selling 3,352 shares during the period. Resona Asset Management Co. Ltd.’s holdings in IQVIA were worth $11,936,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Ameliora Wealth Management Ltd. bought a new position in IQVIA in the fourth quarter worth about $25,000. International Assets Investment Management LLC purchased a new stake in IQVIA in the fourth quarter worth about $27,000. Activest Wealth Management grew its holdings in IQVIA by 590.0% in the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after purchasing an additional 118 shares during the period. Physician Wealth Advisors Inc. grew its holdings in IQVIA by 1,340.0% in the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after purchasing an additional 134 shares during the period. Finally, Westside Investment Management Inc. grew its holdings in IQVIA by 219.6% in the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after purchasing an additional 101 shares during the period. 89.62% of the stock is owned by institutional investors.

IQVIA Trading Down 1.0%

NYSE:IQV opened at $171.47 on Thursday. The company’s 50 day moving average price is $169.85 and its 200-day moving average price is $198.11. IQVIA Holdings Inc. has a 52 week low of $134.65 and a 52 week high of $247.04. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The stock has a market cap of $28.62 billion, a price-to-earnings ratio of 21.25, a PEG ratio of 1.66 and a beta of 1.18.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The firm had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same quarter in the prior year, the company posted $2.70 earnings per share. The business’s revenue for the quarter was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, equities research analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA announced that its Board of Directors has initiated a stock buyback program on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to buy up to 6.8% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s management believes its stock is undervalued.

Analyst Upgrades and Downgrades

IQV has been the topic of a number of recent research reports. BMO Capital Markets set a $250.00 price objective on shares of IQVIA in a report on Friday, February 6th. Royal Bank Of Canada initiated coverage on shares of IQVIA in a report on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 price objective on the stock. UBS Group cut their price objective on shares of IQVIA from $280.00 to $240.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Citigroup cut their price objective on shares of IQVIA from $230.00 to $200.00 and set a “neutral” rating on the stock in a report on Friday, February 6th. Finally, Truist Financial cut their price objective on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a report on Thursday, February 19th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $225.69.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.